Mesalamine suppository

Proctitis Mesalamine suppository 1 g rectally daily May reduce suppository frequency to 1 g 3 times/week... 

Proctitis Mesalamine suppository 1 g rectally daily If no response to mesalamine Prednisone 40-60 mg/day orally May reduce suppository frequency to 1 g 3 times/week taper prednisone as soon as possible Consider adding azathioprine or 6-MP 1.5-2.5 mg/kg per day orally... 

Maintenance of remission of ulcerative colitis may be achieved with oral or topical aminosalicylates. Mesalamine suppositories 1 g daily may prevent relapse in up to 90% of patients with proctitis.1 Mesalamine enemas are appropriate for left-sided disease and may often be dosed three times weekly. Oral mesalamine at lower doses (e.g., 1.6 g per day) may be combined with topical therapies to maintain remission. Topical or oral corticosteroids are not effective for maintaining remission of distal UC and should be avoided. 

Mesalamine—Swallow tablets whole do not chew them. For the suppository, remove foil wrapper and immediately insert tiie pointed end into the rectum without using force. For tiie suspension form, instructions are included with the product. Shake well, remove the protective sheath from the applicator tip, and gently insert the tip into the rectum. Partially intact tablets may be found in the stool if this occurs, notify the primary health care provider. 

Treatment of acute episodes of ulcerative colitis is dictated by the severity and extent of disease, and first-line therapy of mild to moderate disease involves oral or topical aminosalicylate derivatives. Topical suppositories and enemas are preferred for active distal UC (left-sided disease and proctitis), as they deliver mesalamine directly to the site of inflammation. Topical mesalamine is superior to both topical corticosteroids and oral aminosalicylates for inducing remission in active mild to moderate UC.1,33,34 Enemas are appropriate for patients with... 

Mesalamine (Asacol, Pentasa, Rowasa) Ulcerative colitis Tab 400 mg Cap 250 mg Suppository 500 mg Rectal susp 4000 mg/60 mL... 

To avoid the side effects of sulfapyridine, various preparations to target 5-ASA directly to sites of disease have been formulated. Also known as mesalamine, 5-ASA has been formulated in oral forms (Pentasa, Asacoi). Pentasa is a time-release capsule that releases the drug throughout the GI tract. Asacoi is a pH-dependent-release preparation that delivers drug to the distal small bowel and colon. The response of ulcerative colitis to this formulation appears to be identical to that seen with sulfasalazine. Mesalamine can also be administered as a suppository (Canasa) or enema (Rowasa) for distal colonic disease. 

The effectiveness of 5-ASA therapy depends in part on achieving high drug concentration at the site of active disease. Thus, 5-ASA suppositories or enemas are useful in patients with ulcerative colitis or Crohn s disease confined to the rectum (proctitis) or distal colon (proctosigmoiditis). In patients with ulcerative colitis or Crohn s colitis that extends to the proximal colon, both the azo compounds and mesalamine formulations are useful. For the treatment of Crohn s disease involving the small bowel, mesalamine compounds, which release 5-ASA in the small intestine, have a theoretic advantage over the azo compounds. 

Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000 95(7) 1749-54. 

Mesalamine (5-aminosalicylic acid asacol, others) is a salicylate that is used for its local effects in the treatment of inflammatory bowel disease (see Chapter 38). It currently is available as a suppository and rectal suspension enema (rowasa) for treatment of mild-to-moderate proctosigmoiditis Cl rectal suppository (canasa, others) for the treatment of distal ulcerative colitis, proctosigmoiditis, or proctitis. Oral formulations and controlled-release capsule that deliver drug to the lower intestine are efficacious in treatment of inflammatory bowel disease, in particular ulcerative colitis. Sulfasalazine (salicylazosulfapyridine azulfidine) contains mesalamine linked covalently to sulfapyridine (see Chapter 38) it is absorbed poorly after oral administration, but it is cleaved to its active components by bacteria in the colon. The drug is of benefit in the treatment of inflammatory bowel disease, principally because of the local actions of mesalamine. 

Topical preparations of mesalamine suspended in a wax matrix suppository (rowasa) or in a suspension enema (canasa) are effective in active proctitis and distal ulcerative colitis, respectively. They appear to be superior to topical hydrocortisone in this setting, with response rates of 75-90%. Mesalamine enemas (4 g/60 mL) should be used at bedtime and retained for at least 8 hours the suppository (500 mg) should be used two to three times a day with the objective of retaining it for at least 3 hours. Response to local therapy with mesalamine may occur within 3-21 days however, the usual course of therapy is from 3-6 weeks. Once remission has occurred, lower doses are used for maintenance. 

The client diagnosed with inflammatory bowel disease is prescribed mesalamine (Asacol), an aspirin product, suppositories. Which statement indicates the client understands the medication teaching ... 

Mishra MU et al. prepared rectal suppositories of mesalamine by using Sal fat and evaluated several important in vitro characteristics by comparing with the suppositories composed of cocoa butter as standard base. Their findings indicated that Sal fat can be a novel and cost effective suppository base for pharmaceutical formulations. 

---